The New Face of M&A in the Life Sciences Industry: Impacts from Antitrust to IP and Beyond

July 26, 2018 11:45am

Rhiannon I. D’Agostin
Shareholder
Polsinelli PC (Denver, CO)

Elona Kogan
Former General Counsel and Senior Vice President of Government Relations
ARIAD Pharmaceuticals, Inc. (Cambridge, MA)

Jeny Maier
Partner
Axinn, Veltrop & Harkrider LLP (Washington, DC)

Dr. Christine Siegwarth Meyer
Managing Director
NERA Economic Consulting (White Plains, NY)

Jennifer L. Porter
Partner
Pepper Hamilton LLP (Philadelphia, PA)

Over the past year, it has become apparent that M&A in the Life Sciences Industry is evolving. Just when we had gotten a handle on the traditional pharma to pharma merger, now a new layer of complexity has been added by the emerging trend of these organizations merging with or being bought out by tech, biotech, and even retail companies. As we have seen from past M&A transactions, nearly every professional in this industry will be affected by it at some point, and in this situation possibly more than ever. Our experienced panelists will help you understand the far-reaching impacts of these transactions, how those in other practice areas will be impacted, and the common issues attorneys face when working with companies unfamiliar to the challenges of complying with life sciences regulations.